Sugi Predict

Sugi Predict / Compounds / SCHEMBL697598

SCHEMBL697598

SCHEMBL697598

CS(=O)(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.46
▸ HTT P42858 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ MMP12 P39900 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ HSD17B10 Q99714 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ACE P12821 4/20 0.41
▸ REN P00797 2/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ F2 P00734 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PEPD P12955 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153775 1.00 POLB (0.50) POLBALDH1A1HTTMMP8MMP12
SCHEMBL697597 1.00 POLB (0.50) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327498 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327496 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL14594697 0.94 ALDH1A1 (0.53) POLBALDH1A1HTTMMP8MMP12
SCHEMBL17327489 0.89 ALDH1A1 (0.41) POLBALDH1A1HTTMMP8MMP12
SCHEMBL15746879 0.83 TSHR (0.37) POLBALDH1A1HTTKDM4E
SCHEMBL16886885 0.82 PLAU (0.36) POLBALDH1A1KDM4E
SCHEMBL16886888 0.82 PLAU (0.36) POLBALDH1A1KDM4E
SCHEMBL3068881 0.82 PER2 (0.38) POLBALDH1A1MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114437113-B Thiazolopyridine cyclotriazole compound, and preparation method and application thereof 西安交通大学 2023-05-02 — — CN claimed
CN-114573567-B Indazole cyclotriazole compound and preparation method and application thereof 西安交通大学 2023-05-02 — — CN claimed
CN-114573567-A Indazole cyclic triazole compound and preparation method and application thereof 西安交通大学 2022-06-03 — — CN claimed
CN-114437113-A Thiazolopyridine ring-linked triazole compound and preparation method and application thereof 西安交通大学 2022-05-06 — — CN claimed
US-20070191406-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-08-16 — — US claimed
EP-4631573-A2 TEAD INHIBITORS Orion Corporation (FI) 2025-10-15 — — EP disclosed
EP-4323338-B1 TEAD INHIBITORS ORION CORP (FI) 2025-10-08 — — EP disclosed
CN-116640798-B Salt stress analysis method of alfalfa gene promoter 鲁东大学 2025-07-29 — — CN disclosed
CN-113195053-B Amino acid compounds and methods of use 普利安特治疗公司 2024-08-30 — — CN disclosed
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 — — US disclosed
US-20240246908-A1 TEAD INHIBITORS ORION CORPORATION (FI) 2024-07-25 — — US disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
WO-2007093515-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN LA-ROCHE AG (CH) 2007-08-23 — — WO disclosed
US-20070191406-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-08-16 — — US disclosed
CN-1771050-A macrocyclic inhibitors of hepatitis c serine protease ENANTA PHARM INC (US) 2006-05-10 — — CN disclosed
US-20030114514-A1 Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses BIOGEN IDEC MA INC. 2003-06-19 — — US disclosed
EP-1253923-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA 1 INTEGRIN COMPOUNDS AND USES BIOGEN, INC. (US) 2002-11-06 — — EP disclosed
US-20020091142-A1 Alpha4beta1 and alpha4beta7 integrin inhibitors COOKE NIGEL GRAHAM (US) 2002-07-11 — — US disclosed
WO-2001068586-A2 α4β1 AND α4β7 INTEGRIN INHIBITORS NOVARTIS AG (CH) 2001-09-20 — — WO disclosed
WO-2001054690-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA 1 INTEGRIN COMPOUNDS AND USES BIOGEN, INC. (US) 2001-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091142-A1 Alpha4beta1 and alpha4beta7 integrin inhibitors ITGB1, ITGB4, ITGB7 POLB 3130/4885ALDH1A1 152/4885HTT 4846/4885
US-20070191406-A1 Heterocyclic antiviral compounds CCR5, CX3CR1, CXCR1 POLB 2278/4885ALDH1A1 2289/4885HTT 2886/4885
US-20240246908-A1 TEAD INHIBITORS TEAD3, TEAD1, TEAD2 POLB 4445/4885ALDH1A1 630/4885HTT 3852/4885
US-20030114514-A1 Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses ITGB1, ITGA1, ITGB2 POLB 2196/4885ALDH1A1 675/4885HTT 4314/4885
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 POLB 4437/4885ALDH1A1 2168/4885HTT 4639/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 POLB 4437/4885ALDH1A1 2168/4885HTT 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.